Linked Life Data

11368414

Source:http://linkedlifedata.com/resource/pubmed/id/11368414

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11368414rdf:typepubmed:Citationlld:pubmed
pubmed-article:11368414lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:11368414lifeskim:mentionsumls-concept:C0278488lld:lifeskim
pubmed-article:11368414lifeskim:mentionsumls-concept:C0332174lld:lifeskim
pubmed-article:11368414lifeskim:mentionsumls-concept:C0035020lld:lifeskim
pubmed-article:11368414lifeskim:mentionsumls-concept:C0045093lld:lifeskim
pubmed-article:11368414lifeskim:mentionsumls-concept:C0003234lld:lifeskim
pubmed-article:11368414lifeskim:mentionsumls-concept:C0282460lld:lifeskim
pubmed-article:11368414lifeskim:mentionsumls-concept:C0215136lld:lifeskim
pubmed-article:11368414pubmed:issue1lld:pubmed
pubmed-article:11368414pubmed:dateCreated2001-5-22lld:pubmed
pubmed-article:11368414pubmed:abstractTextA phase II study was performed to investigate the efficacy and tolerability of gemcitabine as third-line chemotherapy for patients with metastatic breast cancer, previously treated with both an anthracycline- and taxane-containing regimen. Twenty-three patients were treated with gemcitabine 1200 mg/m2 in a 30-min infusion on day 1, 8 and 15 of a 28 day cycle. Seventy-four percent of the patients had visceral metastases. No complete or partial responses were observed. Six patients (26%) had stable disease with a median duration of 4.0 months. The median time to progression was 1.9 months and the median survival time was 7.8 months. Neutropenia grade 3 and 4 was observed in four patients (18%). Non-hematological toxicity grade 3 included nausea and vomiting in 14%, skin toxicity in 9% and elevation of transaminases in 23% of the patients. Gemcitabine is ineffective as third-line single agent therapy in patients failing anthracycline and taxane treatment for metastatic breast cancer.lld:pubmed
pubmed-article:11368414pubmed:languageenglld:pubmed
pubmed-article:11368414pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11368414pubmed:citationSubsetIMlld:pubmed
pubmed-article:11368414pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11368414pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11368414pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11368414pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11368414pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11368414pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11368414pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11368414pubmed:statusMEDLINElld:pubmed
pubmed-article:11368414pubmed:monthMarlld:pubmed
pubmed-article:11368414pubmed:issn0167-6806lld:pubmed
pubmed-article:11368414pubmed:authorpubmed-author:VerweijJJlld:pubmed
pubmed-article:11368414pubmed:authorpubmed-author:de WitRRlld:pubmed
pubmed-article:11368414pubmed:authorpubmed-author:SeynaeveCClld:pubmed
pubmed-article:11368414pubmed:authorpubmed-author:BontenbalMMlld:pubmed
pubmed-article:11368414pubmed:authorpubmed-author:van ZuylenCClld:pubmed
pubmed-article:11368414pubmed:authorpubmed-author:SmorenburgC...lld:pubmed
pubmed-article:11368414pubmed:authorpubmed-author:de HeusGGlld:pubmed
pubmed-article:11368414pubmed:issnTypePrintlld:pubmed
pubmed-article:11368414pubmed:volume66lld:pubmed
pubmed-article:11368414pubmed:ownerNLMlld:pubmed
pubmed-article:11368414pubmed:authorsCompleteYlld:pubmed
pubmed-article:11368414pubmed:pagination83-7lld:pubmed
pubmed-article:11368414pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:11368414pubmed:meshHeadingpubmed-meshheading:11368414...lld:pubmed
pubmed-article:11368414pubmed:meshHeadingpubmed-meshheading:11368414...lld:pubmed
pubmed-article:11368414pubmed:meshHeadingpubmed-meshheading:11368414...lld:pubmed
pubmed-article:11368414pubmed:meshHeadingpubmed-meshheading:11368414...lld:pubmed
pubmed-article:11368414pubmed:meshHeadingpubmed-meshheading:11368414...lld:pubmed
pubmed-article:11368414pubmed:meshHeadingpubmed-meshheading:11368414...lld:pubmed
pubmed-article:11368414pubmed:meshHeadingpubmed-meshheading:11368414...lld:pubmed
pubmed-article:11368414pubmed:meshHeadingpubmed-meshheading:11368414...lld:pubmed
pubmed-article:11368414pubmed:meshHeadingpubmed-meshheading:11368414...lld:pubmed
pubmed-article:11368414pubmed:meshHeadingpubmed-meshheading:11368414...lld:pubmed
pubmed-article:11368414pubmed:meshHeadingpubmed-meshheading:11368414...lld:pubmed
pubmed-article:11368414pubmed:meshHeadingpubmed-meshheading:11368414...lld:pubmed
pubmed-article:11368414pubmed:meshHeadingpubmed-meshheading:11368414...lld:pubmed
pubmed-article:11368414pubmed:meshHeadingpubmed-meshheading:11368414...lld:pubmed
pubmed-article:11368414pubmed:meshHeadingpubmed-meshheading:11368414...lld:pubmed
pubmed-article:11368414pubmed:meshHeadingpubmed-meshheading:11368414...lld:pubmed
pubmed-article:11368414pubmed:meshHeadingpubmed-meshheading:11368414...lld:pubmed
pubmed-article:11368414pubmed:year2001lld:pubmed
pubmed-article:11368414pubmed:articleTitlePhase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane.lld:pubmed
pubmed-article:11368414pubmed:affiliationDepartment of Medical Oncology, Rotterdam Cancer Institute (Daniel den Hoed Kliniek) and University Hospital Rotterdam, The Netherlands. smorenburg@vvdh.azr.nllld:pubmed
pubmed-article:11368414pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11368414pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:11368414pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:11368414pubmed:publicationTypeClinical Trial, Phase IIlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11368414lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11368414lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11368414lld:pubmed